Co-Authors
This is a "connection" page, showing publications co-authored by AUNG NAING and AHMED KASEB.
Connection Strength
0.617
-
Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Cancer and Viral Hepatitis: The MD Anderson Cancer Center Experience. Oncologist. 2023 08 03; 28(8):714-721.
Score: 0.234
-
Hepatocellular carcinoma: Where there is unmet need. Mol Oncol. 2015 Oct; 9(8):1501-9.
Score: 0.134
-
Immune Checkpoint Inhibitors Suppress Hepatitis C Virus Replication in Infected Patients With Solid Tumors. Am J Gastroenterol. 2023 09 01; 118(9):1609-1617.
Score: 0.058
-
Phase 1 trial of ADI-PEG20 plus cisplatin in patients with pretreated metastatic melanoma or other advanced solid malignancies. Br J Cancer. 2021 04; 124(9):1533-1539.
Score: 0.050
-
Sofosbuvir-Based Therapy in Hepatitis C Virus-Infected Cancer Patients: A Prospective Observational Study. Am J Gastroenterol. 2019 02; 114(2):250-257.
Score: 0.043
-
Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. Oncotarget. 2016 Oct 11; 7(41):67521-67531.
Score: 0.037
-
Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trials. Oncotarget. 2015 Sep 29; 6(29):28453-62.
Score: 0.034
-
Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials. Oncotarget. 2013 Jan; 4(1):156-65.
Score: 0.028